WEKO3
アイテム
{"_buckets": {"deposit": "3c83e82a-c394-48aa-8b87-afad572ec1b4"}, "_deposit": {"created_by": 3, "id": "19737", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "19737"}, "status": "published"}, "_oai": {"id": "oai:twinkle.repo.nii.ac.jp:00019737", "sets": ["2005"]}, "author_link": ["294405", "294408", "294407", "294406", "294404", "294403"], "item_10001_alternative_title_1": {"attribute_name": "別タイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Intravesical Instillation of Epirubicin after Transurethral Resection for Primary Superficial Bladder Cancer"}]}, "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2006-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "34", "bibliographicPageStart": "31", "bibliographicVolumeNumber": "76", "bibliographic_titles": [{"bibliographic_title": "東京女子医科大学雑誌"}]}]}, "item_10001_creator_2": {"attribute_name": "著者名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "前田, 佳子"}], "nameIdentifiers": [{"nameIdentifier": "294403", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "中澤, 速和"}], "nameIdentifiers": [{"nameIdentifier": "294404", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東間, 紘"}], "nameIdentifiers": [{"nameIdentifier": "294405", "nameIdentifierScheme": "WEKO"}]}]}, "item_10001_date_25": {"attribute_name": "受付日付", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2010-08-10", "subitem_date_issued_type": "Created"}]}, "item_10001_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Intravesical chemotherapy is performed after transurethral resection (TUR) of bladder tumors for reducing the recurrence rate. We determined the difference in response to two medication protocols with Ta/T1 bladder cancer. A total of 29 patients with primary superficial bladder cancer, grade 1 or 2, were entered into a randomized trial. Patients were treated with one of two intravesical adjuvant administration protocols : A or B. All patients were received one instillation of 30 nig of epirubicin (EPI) just after TUR. Group A : Early instillation group : Four instillations were done every 24 hr after the first instillation. After that, five instillations were done every week. Total dosage of EPI was 300 mg. Group B : Late instillation group : Nineteen instillations were performed every two weeks after the first instillation. Total dosage of EPI was 600 mg. The primary endpoint was recurrence which was determined with pathological diagnosis. There was a significant difference in non-recurrence rates after 12 months (A 91.7%, B 52.3%) and 24 months (A 81.5%, B 36.6%). Group A had a significantly better recurrence-free survival than group B (p = 0.03). Total dosage of EPI did not effect on recurrence of bladder cancer. The time to first recurrence was not significantly different. Intravesical instillation for superficial bladder cancer after TUR is effective in increasing the non-recurrence rate with EPI if the correct schedule is chosen.", "subitem_description_type": "Abstract"}]}, "item_10001_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "294406", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "MAEDA, Yoshiko"}]}, {"nameIdentifiers": [{"nameIdentifier": "294407", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "NAKAZAWA, Hayakazu"}]}, {"nameIdentifiers": [{"nameIdentifier": "294408", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "TOMA, Hiroshi"}]}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "東京女子医科大学学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00161368", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0040-9022", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_subject_47": {"attribute_name": "著者キーワード", "attribute_value_mlt": [{"subitem_subject": "bladder cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "transurethral resection", "subitem_subject_scheme": "Other"}, {"subitem_subject": "recurrence", "subitem_subject_scheme": "Other"}, {"subitem_subject": "intravesical chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "epirubicin", "subitem_subject_scheme": "Other"}]}, "item_10001_text_35": {"attribute_name": "著者所属", "attribute_value_mlt": [{"subitem_text_value": "東京女子医科大学東医療センター泌尿器科"}, {"subitem_text_value": "東京女子医科大学東医療センター泌尿器科"}, {"subitem_text_value": "東京女子医科大学医学部泌尿器科学"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-08-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KJ00006017987.pdf", "filesize": [{"value": "356.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 356900.0, "url": {"label": "KJ00006017987.pdf", "url": "https://twinkle.repo.nii.ac.jp/record/19737/files/KJ00006017987.pdf"}, "version_id": "63c34f28-7639-4ecf-bd31-906d1af7bf71"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "表在性膀胱癌に対する経尿道的切除後の塩酸エピルビシン膀胱内注入療法による再発予防効果の検討", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "表在性膀胱癌に対する経尿道的切除後の塩酸エピルビシン膀胱内注入療法による再発予防効果の検討"}]}, "item_type_id": "10001", "owner": "3", "path": ["2005"], "permalink_uri": "http://hdl.handle.net/10470/27036", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-08-10"}, "publish_date": "2010-08-10", "publish_status": "0", "recid": "19737", "relation": {}, "relation_version_is_last": true, "title": ["表在性膀胱癌に対する経尿道的切除後の塩酸エピルビシン膀胱内注入療法による再発予防効果の検討"], "weko_shared_id": -1}
表在性膀胱癌に対する経尿道的切除後の塩酸エピルビシン膀胱内注入療法による再発予防効果の検討
http://hdl.handle.net/10470/27036
http://hdl.handle.net/10470/2703687f0f1fc-5038-4dc0-a4c9-38945ab7f75a
名前 / ファイル | ライセンス | アクション |
---|---|---|
KJ00006017987.pdf (356.9 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-08-10 | |||||
タイトル | ||||||
タイトル | 表在性膀胱癌に対する経尿道的切除後の塩酸エピルビシン膀胱内注入療法による再発予防効果の検討 | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
別タイトル | ||||||
その他のタイトル | Intravesical Instillation of Epirubicin after Transurethral Resection for Primary Superficial Bladder Cancer | |||||
著者名 |
前田, 佳子
× 前田, 佳子× 中澤, 速和× 東間, 紘 |
|||||
著者別名 | ||||||
姓名 | MAEDA, Yoshiko | |||||
著者別名 | ||||||
姓名 | NAKAZAWA, Hayakazu | |||||
著者別名 | ||||||
姓名 | TOMA, Hiroshi | |||||
出版者 | ||||||
出版者 | 東京女子医科大学学会 | |||||
受付日付 | ||||||
日付 | 2010-08-10 | |||||
日付タイプ | Created | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0040-9022 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00161368 | |||||
書誌情報 |
東京女子医科大学雑誌 巻 76, 号 1, p. 31-34, 発行日 2006-01 |
|||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Intravesical chemotherapy is performed after transurethral resection (TUR) of bladder tumors for reducing the recurrence rate. We determined the difference in response to two medication protocols with Ta/T1 bladder cancer. A total of 29 patients with primary superficial bladder cancer, grade 1 or 2, were entered into a randomized trial. Patients were treated with one of two intravesical adjuvant administration protocols : A or B. All patients were received one instillation of 30 nig of epirubicin (EPI) just after TUR. Group A : Early instillation group : Four instillations were done every 24 hr after the first instillation. After that, five instillations were done every week. Total dosage of EPI was 300 mg. Group B : Late instillation group : Nineteen instillations were performed every two weeks after the first instillation. Total dosage of EPI was 600 mg. The primary endpoint was recurrence which was determined with pathological diagnosis. There was a significant difference in non-recurrence rates after 12 months (A 91.7%, B 52.3%) and 24 months (A 81.5%, B 36.6%). Group A had a significantly better recurrence-free survival than group B (p = 0.03). Total dosage of EPI did not effect on recurrence of bladder cancer. The time to first recurrence was not significantly different. Intravesical instillation for superficial bladder cancer after TUR is effective in increasing the non-recurrence rate with EPI if the correct schedule is chosen. | |||||
著者所属 | ||||||
東京女子医科大学東医療センター泌尿器科 | ||||||
著者所属 | ||||||
東京女子医科大学東医療センター泌尿器科 | ||||||
著者所属 | ||||||
東京女子医科大学医学部泌尿器科学 | ||||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | bladder cancer | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | transurethral resection | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | recurrence | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | intravesical chemotherapy | |||||
著者キーワード | ||||||
主題Scheme | Other | |||||
主題 | epirubicin |